ASTRO awards $240,000 to four cancer researchers

September 12, 2006

The American Society for Therapeutic Radiology and Oncology is pleased to announce the recipients of its 2006 Junior Faculty Career Research Training Award and Resident/Fellow in Radiation Oncology Research Seed Grants. The total value of the awards is $240,000.

"Educational support by the way of grants is an excellent motivator for these doctors to continue their research and work to find a cure for cancer," said ASTRO President K. Kian Ang, M.D., Ph.D. "I'm confident that the important research conducted by these investigators will help us get another step closer to eradicating cancer."

The ASTRO Junior Faculty Career Research Training Award is designed to stimulate interest in radiation research early in academic career development by giving junior physician-faculty the opportunity to focus on radiation-related research in radiation oncology, biology, physics or outcomes research. The award is $150,000 per year and can be reapplied to for up to an additional two years. This year's recipient is Andy J. Minn, M.D., Ph.D.

Dr. Minn received his undergraduate education from the University of Chicago where he graduated Phi Beta Kappa with a B.A. in biology. He continued his education at the University of Chicago where he received a Ph.D. in Immunology as well as his M.D. Dr. Minn is currently an instructor in the Department of Radiation and Cellular Oncology and an investigator in the Center for Molecular Oncology at the University of Chicago. The title of his project is, "Using De Novo Gene Expression Signature for Chemoradiation Resistance and Metastasis to Develop Clinical Classifiers and to Understand Biological Mechanism."

The ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant is designed to support residents or fellows who are planning a career that focuses primarily on basic science or clinical research. It is designed for the exceptional trainee, and implies commitment to a career in research. Grants of up to $30,000 will be awarded for a one-year project. Recipients chosen for 2006 are Roberto Diaz, M.D., Ph.D., Max Diehn, M.D., Ph.D., and Aaron C. Spalding, M.D., Ph.D.

Dr. Diaz received his undergraduate education from the Manhattanville College in Purchase, N.Y., where he graduated summa cum laude with a B.A. in chemistry. He continued on to New York University where he received a Ph.D. in Basic Medical Sciences and an M.D. He is currently a radiation oncology resident at Vanderbilt University Medical Center in Nashville, Tenn. His project is titled "Rapid Assessment of Cancer Susceptibility to Molecular Targeted Therapy."

Dr. Diehn received his undergraduate education from Harvard University where he graduated summa cum laude with a B.A. in biochemical sciences. He continued his education at Stanford where he received his Ph.D. and M.D. He is currently completing his residency in radiation oncology at Stanford University Hospital in Stanford, Calif. The title of his project is "Molecular Profiling of Human Cancer Stem Cells and Analysis of Their Sensitivity to Ionizing Radiation."

Dr. Spalding received his undergraduate education from the University of Michigan where he graduated with a B.S. in Human Physiology with high honors and distinction. He continued his education at the University of Colorado where he received a Ph.D. in Pharmacology and an M.D. He is currently conducting post-graduate work as a B. Leonard Holman Pathway Resident in the Department of Radiation Oncology at the University of Michigan, in Ann Arbor, Mich. The title of his project is "Targeting Protein Kinase Cbeta for Radiosensitization in Pancreatic Cancer."
-end-
Photographs of these individuals are available by contacting Julie Moore at juliem@astro.org or 1-800-962-7876. For more information on ASTRO's awards, visit http://www.astro.org/research/funding_opportunities/astro_awards/index.htm.

ASTRO is the largest radiation oncology society in the world, with more than 8,500 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to the advancement of the practice of radiation oncology by promoting excellence in patient care, providing opportunities for educational and professional development, promoting research and disseminating research results and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment.

American Society for Radiation Oncology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.